Table 4 (A) Relative monitoring frequency for each csDMARD compared to methotrexate by respondent percentage, N = 187#; (B) change in monitoring frequency for each csDMARD combination by respondent percentage, N = 173#; (C) change in monitoring frequency for each co-morbidity by respondent percentage, N = 173#
A: csDMARD | More (N, %)* | Less (N, %)* | Equal (N, %)* | No monitoring (N, %)* | Not prescribed (N, %)* |
|---|---|---|---|---|---|
(A) | |||||
Leflunomide | 8 (4%) | 8 (4%) | 168 (90%) | 0 (0%) | 3 (2%) |
Sulfasalazine | 12 (6%) | 75 (40%) | 97 (52%) | 1 (1%) | 2 (1%) |
Hydroxychloroquine | 0 (0%) | 81 (43%) | 20 (11%) | 86 (46%) | 0 (0%) |
Azathioprine | 33 (18%) | 7 (4%) | 141 (75%) | 1 (1%) | 5 (3%) |
Mycophenolate | 26 (14%) | 11 (6%) | 142 (76%) | 0 (0%) | 8 (4%) |
Tacrolimus and other calcineurin inhibitors | 30 (16%) | 4 (2%) | 81 (43%) | 4 (2%) | 68 (36%) |
csDMARD combination | More (N, %)* | Less (N, %)* | Equal (N, %)* | Not prescribed (N, %)* | |
|---|---|---|---|---|---|
(B) | |||||
Methotrexate/leflunomide | 76 (44%)* | 0 (0%) | 73 (42%) | 24 (14%) | |
Methotrexate/sulfasalazine | 19 (11%) | 2 (1%) | 145 (84%) | 7 (4%) | |
Methotrexate/hydroxychloroquine | 4 (2%) | 3 (2%) | 166 (96%) | 0 (0%) | |
Sulfasalazine/hydroxychloroquine | 3 (2%) | 16 (9%) | 147 (85%) | 7 (4%) | |
Leflunomide/hydroxychloroquine | 6 (3%) | 3 (2%) | 154 (89%) | 10 (6%) | |
Sulfasalazine/leflunomide | 28 (16%) | 2 (1%) | 131 (76%) | 12 (7%) | |
Co-morbidity | More (N, %)* | Less (N, %)* | Equal (N, %)* | Cease csDMARD (N, %)* | |
|---|---|---|---|---|---|
(C) | |||||
Obesity | 26 (15%)* | 1 (1%) | 146 (84%) | 0 (0%) | |
Fatty liver disease | 120 (69%) | 2 (1%) | 51 (29%) | 0 (0%) | |
Other liver disease | 126 (73%) | 2 (1%) | 35 (20%) | 10 (6%) | |
Alcohol intake above NHMRC Guideline | 104 (60%) | 1 (1%) | 47 (27%) | 21 (12%) | |
Existing cytopenias | 145 (84%) | 0 (0%) | 19 (11%) | 9 (5%) | |
eGFR < 30 | 121 (70%) | 1 (1%) | 20 (12%) | 31 (18%) | |
eGFR 30–60 | 75 (43%) | 3 (2%) | 93 (54%) | 2 (1%) | |
18–60 years old | 3 (2%) | 8 (5%) | 162 (94%) | 0 (0%) | |
60–80 years old | 33 (19%) | 4 (2%) | 136 (79%) | 0 (0%) | |
> 80 years old | 78 (45%) | 2 (1%) | 89 (51%) | 4 (2%) | |